Overview of Cafenol
| Property | Description |
|---|---|
| Active ingredients | Acetaminophen (Paracetamol) and Caffeine |
| Form | Oral solid dosage form (Tablet) |
| Pharmacological class | Combination Analgesic (Non-opioid) |
| Common use | Temporary relief of discomfort and fever |
| Origin | Synthetic chemical compounds |
Cafenol is a widely used polycomponent analgesic defined as a fixed-dose combination preparation, containing two distinct active ingredients of synthetic origin. This classification indicates that the medicine is specifically formulated to utilize the combined effects of its components for enhanced therapeutic results. As an Over-the-Counter (OTC) medicine, its primary purpose, clinically recognized across general pharmaceutical practice, is the efficient, temporary, and symptomatic relief of general discomfort and fever.
Classification and Composition
Cafenol is classified as an Analgesic Combination product, primarily comprising the non-opioid pain reliever, Acetaminophen, and Caffeine, a CNS Stimulant from the methylxanthine class. The product's fundamental pharmacological class is derived from the main ingredient, Acetaminophen, a universally recognized antipyretic (fever reducer) and analgesic (pain reliever). The tablet is intended for the oral route of administration and is manufactured as an oral solid dosage form.
The Role of Caffeine and General Purpose
The inclusion of Caffeine in this formulation serves as an adjuvant (helper substance), a role recognized in combination analgesics. The simultaneous administration of these two agents in a fixed dose is intended to offer enhanced efficacy for acute pain relief compared to Acetaminophen administered alone. This means the synergistic action is specifically intended to improve the speed of relief and overall effectiveness for the patient, which is a key differentiating factor from single-ingredient pain relievers. Consequently, the general purpose of Cafenol is to provide enhanced, temporary relief of common symptoms involving discomfort and fever by leveraging this established pharmacological synergy.
Regulatory References


